Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.
Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.
复制标题
DOI：
10.14740/jocmr4037
复制
发表时间：
2020-01-01
期刊：
影响因子：
--
通讯作者：
Kataoka, Hiromi
中科院分区：
文献类型：
--
作者：
Tanida, Satoshi;Ozeki, Keiji;Kataoka, Hiromi
背景技术背景：强化粒细胞和单核细胞吸附性单采术（GMA）或Janus激酶（JAK）抑制剂单药治疗仅限于难治性溃疡性结肠炎（UC）患者。托法替尼（TOF）联合强化GMA治疗的疗效和安全性方法：本回顾性研究评价了TOF联合强化GMA治疗难治性UC患者的10周疗效。结果：在接受TOF加强化GMA联合治疗的7例患者中，71.4%在10周时达到临床缓解。10周时粘膜愈合和完全粘膜愈合的患者百分比分别为100%和42.9%。基线时平均马约评分和内镜分项评分分别为8.71 ± 0.80和2.4 ± 0.2，10周时相应值分别为1.57 ± 0.48和0.6 ± 0.2（P < 0.01）。口唇疱疹和肌酐磷酸激酶（CK）和甘油三酯的暂时增加的不良事件观察在3 patients.Conclusions：基于这些结果，TOF加强化GMA联合治疗耐受性良好，可能是有用的诱导难治性UC患者的临床缓解。
BACKGROUND: The use of monotherapy with intensive granulocyte and monocyte adsorptive apheresis (GMA) or a Janus kinase (JAK) inhibitor has been limited to patients with refractory ulcerative colitis (UC). The efficacy and safety of combination therapy with tofacitinib (TOF) plus intensive GMA (two sessions per week) for refractory UC have not been evaluated.METHODS: This retrospective study evaluated the 10-week efficacy of combination therapy with TOF plus intensive GMA in patients with refractory UC.RESULTS: Of seven patients who received a combination therapy with TOF plus intensive GMA, 71.4% achieved clinical remission at 10 weeks. The percentages of patients with mucosal healing and complete mucosal healing at 10 weeks were 100% and 42.9%, respectively. The mean full Mayo score and endoscopic subscore at baseline were 8.71 ± 0.80 and 2.4 ± 0.2, respectively, and the corresponding values at 10 weeks were 1.57 ± 0.48 and 0.6 ± 0.2 (P < 0.01), respectively. Adverse events of an orolabial herpes and temporary increase in creatinine phosphokinase (CK) and triglyceride were observed in three patients.CONCLUSIONS: Based on these outcomes, combination therapy with TOF plus intensive GMA was well tolerated and may be useful for induction of clinical remission in patients with refractory UC.